Romiplostim plus standard therapy for severe aplastic anemia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether adding romiplostim, a drug that helps the body make platelets, to the usual treatment for severe aplastic anemia can improve blood cell counts. It is for people who have not yet started treatment for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years or older.
- You have been diagnosed with severe or very severe aplastic anemia, meaning your bone marrow is not making enough blood cells.
- You have not yet received certain treatments for aplastic anemia, like ATG, cyclosporine (for more than 4 weeks), or other platelet-boosting drugs.
- You have not had a stem cell transplant.
- You do not have other bone marrow diseases or certain infections (like active CMV or EBV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs to help your bone marrow make more blood cells if you have aplastic anemia and cannot have a stem cell transplant or standard immune therapy. It might improve blood counts and reduce the need for transfusions.
This study tests a medication called romiplostim, which helps the body make more blood cells, for children and young adults with severe aplastic anemia. It may help improve blood counts and reduce the need for transfusions.
This trial tests a drug called romiplostim for people with aplastic anemia that did not get better with standard treatments. It aims to boost blood cell counts and may help reduce the need for transfusions.
This trial tests whether a new combination of medicines can help treat severe aplastic anemia (SAA) or a related type (TD-NSAA). It uses a drug that helps your body make more platelets, along with immunosuppressants, and may offer an alternative if a bone marrow transplant isn't possible.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
Hear when a new Treatment-naïve Severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.